PainReform (PRFX) Competitors $1.49 +0.04 (+2.83%) As of 11:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. CVM, GOVX, MBIO, CYCN, PHXM, ARTL, SNSE, LSB, GLYC, and GNPXShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include CEL-SCI (CVM), GeoVax Labs (GOVX), Mustang Bio (MBIO), Cyclerion Therapeutics (CYCN), PHAXIAM Therapeutics (PHXM), Artelo Biosciences (ARTL), Sensei Biotherapeutics (SNSE), LakeShore Biopharma (LSB), GlycoMimetics (GLYC), and Genprex (GNPX). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors CEL-SCI GeoVax Labs Mustang Bio Cyclerion Therapeutics PHAXIAM Therapeutics Artelo Biosciences Sensei Biotherapeutics LakeShore Biopharma GlycoMimetics Genprex CEL-SCI (NYSE:CVM) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Do institutionals and insiders believe in CVM or PRFX? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 9.9% of CEL-SCI shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is CVM or PRFX more profitable? PainReform's return on equity of 0.00% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% PainReform N/A N/A N/A Do analysts rate CVM or PRFX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, CVM or PRFX? CEL-SCI has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Which has better earnings and valuation, CVM or PRFX? CEL-SCI is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$12.61-0.32PainReformN/AN/A-$14.59M-$147.33-0.01 Does the media favor CVM or PRFX? In the previous week, CEL-SCI had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for CEL-SCI and 0 mentions for PainReform. CEL-SCI's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score. Company Overall Sentiment CEL-SCI Neutral PainReform Neutral SummaryPainReform beats CEL-SCI on 8 of the 10 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.02M$2.44B$5.51B$9.47BDividend YieldN/A1.80%4.00%4.04%P/E Ratio-0.018.8528.1819.90Price / SalesN/A735.79426.8892.15Price / CashN/A22.4924.9928.17Price / Book0.725.028.275.77Net Income-$14.59M$30.99M$3.24B$257.79M7 Day Performance6.50%2.53%1.80%2.77%1 Month Performance-7.10%12.31%9.32%14.17%1 Year Performance-26.19%2.15%35.12%20.71% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReformN/A$1.49+2.8%N/A-28.2%$3.02MN/A-0.014Gap DownCVMCEL-SCI0.1223 of 5 stars$3.63+2.8%N/A-90.0%$11.01MN/A-7.5643High Trading VolumeGOVXGeoVax Labs2.1616 of 5 stars$0.69+1.4%$11.10+1,520.2%-72.9%$10.91M$3.95M-0.1910Analyst DowngradeMBIOMustang Bio0.732 of 5 stars$2.42-8.7%N/A-86.4%$10.60MN/A-0.03100Analyst UpgradeGap DownCYCNCyclerion Therapeutics0.9648 of 5 stars$3.30-9.3%N/A+6.9%$10.59M$2M-2.8430Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ARTLArtelo Biosciences2.1278 of 5 stars$18.55-22.3%$25.00+34.8%+71.8%$10.20MN/A-1.035Gap DownSNSESensei Biotherapeutics4.3676 of 5 stars$8.08-1.1%$90.00+1,013.9%-41.4%$10.19MN/A-0.3540Positive NewsLSBLakeShore Biopharma0.3526 of 5 stars$1.11+2.8%N/A-78.8%$10.05M$80.82M0.00773Gap DownGLYCGlycoMimeticsN/A$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450High Trading VolumeGNPXGenprex0.739 of 5 stars$0.30+8.3%N/A-85.7%$9.95MN/A0.0020Positive News Related Companies and Tools Related Companies CVM Competitors GOVX Competitors MBIO Competitors CYCN Competitors PHXM Competitors ARTL Competitors SNSE Competitors LSB Competitors GLYC Competitors GNPX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
